This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody & ADC Summit At ChinaBio
Shanghai, China
Kerry Hotel Pudong, Shanghai, ChinaApril 28–29, 2026

Dr. Zou Bin, PhD
Founder and CEO at Axcynsis Therapeutics
Speaker

Profile

Zou Bin is a seasoned executive and has helmed many leadership positions. He is currently an Adjunct Associate Professor at National University of Singapore. Previously, he served as Managing Director at Trinity Innovation Bioventure Singapore (TIBS) and was the CEO of Shanghai Blueray Biopharma where he successfully led the team to develop several candidates into investigational new drug (IND) stage. Prior to his venture, Dr. Zou was a Principal Scientist at Novartis Institute for Tropical Disease where he spearheaded the team to the discovery of Phase II clinical trials drug NITD609. He is the author to more than 25 peer reviewed publications.

Agenda Sessions

  • Panel Discussion: East Meets West: China's Market Dynamics and Global Investment Trends Shaping the Future of ADC Therapies

    11:15
  • Axcynsis Dual Payload Technology Platform: Anti-ROR1 ADC Discovery

    14:45